Savant Capital LLC Lowers Stake in Gilead Sciences Inc. (GILD)
Savant Capital LLC lowered its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,854 shares of the biopharmaceutical company’s stock after selling 26 shares during the period. Savant Capital LLC’s holdings in Gilead Sciences were worth $739,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the stock. Joel Isaacson & Co. LLC raised its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares in the last quarter. Jolley Asset Management LLC raised its stake in Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares in the last quarter. North Star Investment Management Corp. raised its stake in Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 700 shares in the last quarter. Finally, Peoples Financial Services CORP. raised its stake in Gilead Sciences by 30.4% in the second quarter. Peoples Financial Services CORP. now owns 2,575 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 600 shares in the last quarter. Institutional investors own 78.00% of the company’s stock.
Gilead Sciences Inc. (NASDAQ:GILD) traded up 1.06% during mid-day trading on Tuesday, hitting $73.41. The stock had a trading volume of 6,353,498 shares. Gilead Sciences Inc. has a 52-week low of $72.21 and a 52-week high of $111.11. The stock has a market cap of $96.88 billion, a P/E ratio of 6.44 and a beta of 1.10. The firm has a 50-day moving average of $77.59 and a 200-day moving average of $84.05.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period in the prior year, the firm posted $3.15 earnings per share. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. On average, analysts forecast that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s payout ratio is 16.56%.
GILD has been the subject of several recent research reports. Jefferies Group boosted their price target on Gilead Sciences from $91.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday, October 5th. Piper Jaffray Cos. reissued a “buy” rating and set a $108.00 price target on shares of Gilead Sciences in a report on Monday, August 15th. Berenberg Bank initiated coverage on Gilead Sciences in a report on Thursday, September 22nd. They set a “buy” rating for the company. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Sunday, July 10th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 6th. Ten investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average price target of $102.78.
In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $79.81, for a total value of $159,620.00. Following the sale, the executive vice president now owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total value of $7,763,000.00. Following the sale, the insider now directly owns 3,231,096 shares in the company, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.